Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05821088 · ClinicalTrials.gov registry record · Phase 2
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
A Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma, sponsored by David Bond, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT05821088 is a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma that is actively recruiting participants, run by David Bond, MD. The registered enrollment target is 37 participants, roughly in line with the 38-participant average among 8 other Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT05821088, a Phase 2 study of Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified and Recurrent Grade 3b Follicular Lymphoma, is actively recruiting participants, sponsored by David Bond, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide may have antineoplastic activity which may help block the formation of growths that may become cancer. Drugs used in chemotherapy, such as carboplatin, etoposide and ifosfamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tafasitamab and lenalidomide followed by ICE may be a better treatment for patients with relapsed or refractory large B-cell lymphomas.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- DRUG Etoposide
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05821088
The ClinicalTrials.gov registry entry for NCT05821088 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 38-participant average among 8 other Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials with a reported enrollment target. The listed sponsor is David Bond, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT05821088 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05821088 about?
NCT05821088 is a clinical study titled "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma". This phase II clinical trial evaluates tafasitamab and lenalidomide followed by tafasitamab and the carboplatin, etoposide and ifosfamide (ICE) regimen as salvage therapy for transplant eligible patients with large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refr...
What is the current status of trial NCT05821088?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2023-06-29. Estimated completion is 2026-12-31.
What conditions does trial NCT05821088 study?
This clinical trial studies the following conditions: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements.
What interventions are being tested in trial NCT05821088?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Etoposide (DRUG).
Who is sponsoring clinical trial NCT05821088?
This trial is sponsored by David Bond, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05821088 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
RECRUITING · Phase 2
-
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
RECRUITING · Phase 2
-
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RECRUITING · Phase 2
-
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
All registered trials for this condition
Recurrent Grade 3b Follicular Lymphoma
All registered trials for this condition
Ohio
All trials with a study site in Ohio
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.